HIV drug resistance

Viriom Signed Licensing Agreement for Indonesia with P.T. Lloyd Pharma

Retrieved on: 
Tuesday, July 2, 2019
HIV/AIDS, Medical specialties, Viruses, Antivirals, HIV drug resistance, Management of HIV/AIDS, HIV, Medicine

SAN DIEGO, July 2, 2019 /PRNewswire/ --Viriom Inc (San Diego, CA) signed a licensing agreement with P.T.

Key Points: 
  • SAN DIEGO, July 2, 2019 /PRNewswire/ --Viriom Inc (San Diego, CA) signed a licensing agreement with P.T.
  • Lloyd Pharma Indonesia as a part of its global strategy to help combat HIV drug resistance problem in developing markets by using innovative, safe and efficacious treatment and prevention options with Elpida as well as other drugs from Viriom HIV and HBV portfolio.
  • The problem of HIV drug resistance is very important for healthcare in Indonesia and many other developing countries.
  • Lloyd will enable technology transfer, primary and secondary packaging and drug manufacturing in Indonesia.

Global Antiretroviral Market is projected to display a robust growth represented by a CAGR of 4.70% during 2018 - 2023

Retrieved on: 
Wednesday, April 17, 2019
Hepatotoxins, RTT, Prevention of HIV/AIDS, Medical specialties, Chemical substances, Drugs, Reverse-transcriptase inhibitor, Management of HIV/AIDS, Protease inhibitor, Zidovudine, HIV drug resistance, Discovery and development of non-nucleoside reverse-transcriptase inhibitors

The report analyses the Antiretroviral Market By Drug Type (Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others).

Key Points: 
  • The report analyses the Antiretroviral Market By Drug Type (Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others).
  • However, growing portfolio of generic antiretroviral drugs is expected impact the overall market growth.
  • Amongst the regions, North America accounts for the largest regional share in the global antiretroviral market in 2017.
  • Global Antiretroviral Drugs Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)
    Analysis By Drug Type - Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others.

Janssen Presents Switch Data for New HIV-1 Treatment SYMTUZA™ (D/C/F/TAF) and Second Study Supporting its Use in a Rapid Initiation Scenario

Retrieved on: 
Tuesday, July 24, 2018
HIV/AIDS, Medicine, Hepatotoxins, Management of HIV/AIDS, HIV drug resistance, HIV, Clinical medicine, Health

"These data add to the growing body of evidence that supports healthcare professionals to navigate treatment options."

Key Points: 
  • "These data add to the growing body of evidence that supports healthcare professionals to navigate treatment options."
  • DIAMOND is the first Phase 3 trial for a single-tablet regimen conducted in a rapid initiation scenario.
  • "HIV drug resistance and rapid initiation of treatment are key issues in today's HIV care landscape," said Brian Woodfall, M.D.
  • Your healthcare provider may need to do tests to check your liver enzymes before and during treatment with SYMTUZA.